Transforming nature into: better medicine. inflammatory relief. clinical therapeutics. tolerable remedies. faster results. innovative bioactives. metabolic balance. validated solutions.
Developing best-in-class therapeutics that target gout and adjacent inflammatory conditions.
For informational purposes only. No clinical trial has been completed and no product has been approved by the FDA or Health Canada. No claims of safety, efficacy, treatment, or cure are made or implied. All observations are anecdotal and unverified.
About Us
Targeting Gout: the world’s most painful form of arthritis.
Gout is the world's most common and most painful form of inflammatory arthritis.
Prevalence continues to accelerate, yet effective, fast-acting options remain scarce and insufficient for many.
Backed by decades of real-world use.
We work with time-tested, botanically derived bioactive compounds, observed in real-world use long before the lab.
Our signal-first approach delivers safer, more predictable, and more effective clinical development.
In pursuit of clinical validation.
From observation to formulation, we are focused on translating promising solutions into validated, science-driven therapeutics.
Delivering meaningful care for patients around the world.
No product candidate has been approved by the FDA, Health Canada, or any regulatory authority. No clinical trial has been initiated or completed. No claims of safety, efficacy, treatment, or cure are made or implied. All images for illustration purposes only.
Why now
Gout is widespread and growing.
Current options are lacking.
U.S. adults living with gout.
Most common type of inflammatory arthritis.
U.S. gout prevalence more than doubled from 2001 to 2021.
Sources: Chen-Xu et al., 2019 · Arthritis Foundation · ACR Convergence 2024.
A condition this prevalent, painful, and debilitating deserves better-tolerated, faster-acting options.
Epidemiology figures above are drawn from publicly available sources (Chen-Xu et al., Arthritis & Rheumatology, 2019; Arthritis Foundation patient education materials; American College of Rheumatology Convergence 2024 abstract) and describe the condition only. They are not claims about any Celeritas Bioscience product candidate. No clinical trial for CTX-145 has been initiated or completed. No claims of safety, efficacy, treatment, or cure are made or implied.
A natural approach
Botanically derived.
A distinct advantage.
Celeritas focuses on developing botanical drugs: a complex mixture of naturally derived herbal compounds, well observed in real human use for decades.
Botanical drugs deliver distinct advantages over synthetic drugs:
-
01
Better tolerated. Wider therapeutic margin.
Botanical drugs are typically better tolerated than synthetic alternatives, with a superior risk-to-benefit ratio shaped by broad therapeutics margins and low interaction potential.
-
02
Drug-grade rigor. First-line therapies.
Evidence-based botanical drugs are held to the same regulatory standards as synthetic drugs:
randomised controlled trials, defined composition, validated processing. In multiple indications, botanical drugs have become first-line therapy options for their tolerance-to-efficacy profile. -
03
Decades of history and untapped potential.
Recent scientific and regulatory advances have redefined how botanical drugs are evaluated, unlocking new pathways through real-world evidence and modern analytical techniques.
Phytopharmaceutical and botanical drug attributes described above reflect the regulated category in general and are not claims about any specific Celeritas product candidate. Tolerability, benefit–risk, and first-line-therapy references describe approved phytopharmaceutical products in their respective indications and are not predictive of outcomes for any pre-clinical candidate. Documented traditional or real-world use is not a substitute for controlled clinical investigation and does not establish safety or efficacy for any individual candidate. All Celeritas product candidates are pre-clinical. No clinical trial has been initiated or completed. No claims of safety, efficacy, treatment, or cure are made or implied. Forward-looking statements involve substantial risk and uncertainty.
LEAD PROGRAM
CTX-145
CTX-145, our lead candidate, is being advanced for acute gout flare and adjacent inflammatory and metabolic conditions.
- Pre-clinical planning
- Botanically derived bioactives
- Inflammatory and metabolic focus
Highlighted patient-reported signals:
Program descriptions reflect internal development priorities only and are subject to change. No product described herein has been approved, authorized, or cleared by the U.S. Food and Drug Administration (FDA), Health Canada, or any other regulatory authority. No investigational new drug application (IND) or clinical trial application (CTA) has been filed or approved. No clinical trial has been initiated or completed. No claims of safety, efficacy, diagnosis, treatment, cure, mitigation, or prevention of any disease, disorder, or health condition are made or implied. This content is not intended to be and does not constitute medical, legal, financial, or investment advice.
REAL-WORLD EVIDENCE
I suffered an acute gout flare early in the morning. I couldn't go to work, much less get out of bed. After taking one dose the pain that usually lasts days only lasted hours.
— Male, 43, Canada
Anecdotal, self-reported observation. Not a clinical outcome. Has not been verified, replicated, or validated in any controlled clinical trial. No claims of safety, efficacy, treatment, or cure are made or implied.
Differentiation
Real world evidence.
Not blind guesswork.
Existing treatments
- Slow to relieve acute symptoms
- Significant side-effect burden
- Contraindicated in many patient populations
- Limited formulation options
The Celeritas approach
- Botanically derived candidate formulation
- Real-world reported tolerability
- Novel mechanism under investigation
- Designed for acute flare management
Comparative descriptions above represent directional characterizations of the treatment landscape based on published literature and internal assessment only. They do not constitute clinical claims. No head-to-head study comparing CTX-145 to any approved therapy has been conducted. No clinical trial for CTX-145 has been initiated or completed. No product described herein has been approved by the FDA, Health Canada, or any other regulatory authority. All observations regarding CTX-145 are based on anecdotal, patient-reported data only. No claims of safety, efficacy, superiority, treatment, or cure are made or implied.
For investors
Join us in building the future of therapeutics.
Nothing on this website constitutes an offer or solicitation to buy or sell securities.